• Mashup Score: 10

    This cross-sectional study analyzes the smoking status of patients newly diagnosed with cancer, which has implications for cancer care and outcomes.

    Tweet Tweets with this article
    • A study of 1.6 million US cancer patients in 2023 found 47.3% had a smoking history, with 14.7% currently smoking at diagnosis. https://t.co/NYD3WcFlzX https://t.co/L1QBR0cOTk

  • Mashup Score: 2

    This cohort study examines the incidence and proportion of interval cancer and screen-detected breast cancer and identifies factors associated with interval cancer.

    Tweet Tweets with this article
    • Interval breast cancer (IntCa) rates remain high despite mammographic screening, highlighting the need for personalized screening based on risk factors like high breast density, hormone replacement therapy, and family history. https://t.co/2mmvcYtERq https://t.co/0h4GHkn6sO

  • Mashup Score: 15

    Meta-epidemiology addresses methodological biases and variability in research findings across multiple studies. By systematically examining how study design, statistical methods, and study characteristics influence reported outcomes, meta-epidemiology uncovers the sources and impacts of bias,…

    Tweet Tweets with this article
    • Editor's Note: The Role of Meta-Epidemiology in Oncology Research—Bridging Evidence and Practice #ASCO25 https://t.co/ZJlOymMgmN https://t.co/i8W7MTq06U

  • Mashup Score: 250

    This meta-epidemiological study analyzes phase 3 oncology randomized clinical trials to determine the proportions of trials that show improvement in overall survival, quality of life, and alternative end points and compares these outcomes with overall trial interpretation.

    Tweet Tweets with this article
    • Phase 3 oncology RCTs often report positive results based on alternative end points, but actual improvements in overall survival or quality of life are rare, highlighting need to prioritize these outcomes in future research & regulatory processes. #ASCO25 https://t.co/GRGe7FuLqm https://t.co/cQqYTyattX

  • Mashup Score: 5

    This cohort study evaluates the distribution of serum free light chains and free light chain ratios in individuals with preserved kidney function and proposes revised reference intervals and a new definition of light chain monoclonal gammopathy of undetermined significance.

    Tweet Tweets with this article
    • Revised reference intervals for serum free light chains reduced false-positive rates for LC-MGUS diagnosis by 82%. https://t.co/8GJQJHf6po https://t.co/f8c9UfANNy

  • Mashup Score: 28

    This Viewpoint describes a phenomenon termed skimming the median and discusses 3 examples to emphasize why an entire dataset should be considered to reach precise conclusions.

    Tweet Tweets with this article
    • Most viewed this week from @JAMAOnc: Viewpoint discusses how "skimming the median" can exaggerate survival gains in clinical trials, underscoring the need to critically evaluate Kaplan-Meier curves alongside hazard ratios. https://t.co/EtKGuU9u76 https://t.co/fG70VuLdy2

  • Mashup Score: 4

    A 70-year-old man with a history of hypertension and chronic migraine presented with 10 months of progressive generalized muscle weakness and stiffness. Physical examination revealed generalized muscle wasting except for hypertrophy of bilateral shoulder muscles, and a deltoid muscle biopsy revealed…

    Tweet Tweets with this article
    • A 70-year-old man with a history of hypertension and chronic migraine presented with 10 months of progressive generalized muscle weakness and stiffness. Take the Clinical Challenge. https://t.co/hrbnfcANB2

  • Mashup Score: 15

    Meta-epidemiology addresses methodological biases and variability in research findings across multiple studies. By systematically examining how study design, statistical methods, and study characteristics influence reported outcomes, meta-epidemiology uncovers the sources and impacts of bias,…

    Tweet Tweets with this article
    • Editor's Note: The Role of Meta-Epidemiology in Oncology Research—Bridging Evidence and Practice #ASCO25 https://t.co/ZJlOymMgmN https://t.co/i8W7MTq06U

  • Mashup Score: 250

    This meta-epidemiological study analyzes phase 3 oncology randomized clinical trials to determine the proportions of trials that show improvement in overall survival, quality of life, and alternative end points and compares these outcomes with overall trial interpretation.

    Tweet Tweets with this article
    • Phase 3 oncology RCTs often report positive results based on alternative end points, but actual improvements in overall survival or quality of life are rare, highlighting need to prioritize these outcomes in future research & regulatory processes. #ASCO25 https://t.co/GRGe7FuLqm https://t.co/cQqYTyattX